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Abstract
The relationship between tobacco smoking and prostate cancer (PCa) remains
inconclusive. This study examined the association between tobacco smoking
and PCa risk taking into account polymorphisms in carcinogen metabolism
enzyme genes as possible effect modiﬁers (9 polymorphisms and 1 predicted
phenotype from metabolism enzyme genes). The study included cases (n = 761
localized; n = 1199 advanced) and controls (n = 1139) from the multiethnic
California Collaborative Case–Control Study of Prostate Cancer. Multivariable
conditional logistic regression was performed to evaluate the association
between tobacco smoking variables and risk of localized and advanced PCa risk.
Being a former smoker, regardless of time of quit smoking, was associated with
an increased risk of localized PCa (odds ratio [OR] = 1.3; 95% conﬁdence
interval [CI] = 1.0–1.6). Among non-Hispanic Whites, ever smoking was asso-
ciated with an increased risk of localized PCa (OR = 1.5; 95% CI = 1.1–2.1),
whereas current smoking was associated with risk of advanced PCa (OR = 1.4;
95% CI = 1.0–1.9). However, no associations were observed between smoking
intensity, duration or pack-year variables, and advanced PCa. No statistically
signiﬁcant trends were seen among Hispanics or African-Americans. The rela-
tionship between smoking status and PCa risk was modiﬁed by the CYP1A2
rs7662551 polymorphism (P-interaction = 0.008). In conclusion, tobacco smok-
ing was associated with risk of PCa, primarily localized disease among non-His-
panic Whites. This association was modiﬁed by a genetic variant in CYP1A2,
thus supporting a role for tobacco carcinogens in PCa risk.
1644 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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Introduction
Tobacco smoking is associated with an increased risk of
several cancers, yet its carcinogenic role in the prostate is
not clearly established [1, 2]. Whereas several epidemio-
logic studies do not support an association [2], a meta-
analysis of 24 prospective cohort studies reported an esti-
mated overall increased risk of PCa- and PCa-related
mortality associated with tobacco smoking [1]. A 2009
review of the epidemiological literature further supported
an association between tobacco smoking and aggressive
PCa [3]. Possible factors contributing to inconsistencies
in the literature include the heterogeneity in study
designs, the varying smoking status deﬁnitions, the lack
of details on smoking history and cessation, and lack of
consideration of stage and tumor grade. Moreover, risk of
PCa associated with tobacco smoking may also differ by
race/ethnicity. Most studies examining the association
between PCa risk and tobacco smoking predominantly
include non-Hispanic White men, with only a few in
African-Americans (AA) [4, 5] or Hispanics [6].
Tobacco smoke contains a wide variety of chemical car-
cinogens, including polycyclic aromatic hydrocarbons
(PAHs), aromatic amines, heterocyclic amines (HCAs), and
N-nitroso compounds (NOCs) [7]. The prostate gland is
able to metabolize many of these chemicals into activated
carcinogens [8–11], suggesting a plausible link between
tobacco smoking and prostate carcinogenesis. In support of
this, a prior study has reported associations between tobacco
smoking and the presence of PAH-DNA adducts in the pros-
tate, which varied by race and were modiﬁed by genetic vari-
ants involved in PAH metabolism [12]. To date, few studies
have evaluated polymorphisms in tobacco carcinogen
metabolism enzymes as possible modiﬁers of the association
between tobacco consumption and PCa risk, in particular
among different racial/ethnic populations [5, 13, 14].
In this study, we evaluated associations between tobacco
smoking and risk of localized and advanced PCa using data
from the California Collaborative Prostate Cancer Study, a
large population-based case–control study in non-Hispanic
White, AA, and Hispanic men. We also considered the role
of polymorphisms in selected genes that code for tobacco
carcinogens metabolism enzymes (GSTP1, PTGS2,
CYP1A2, CYP2E1, EPHX1, CYP1B1, UGT1A6, NAT2,
GSTM1, and GSTT1) as potential modiﬁers of the relation-
ship between tobacco smoking and PCa risk.
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The California Collaborative Prostate Cancer Study was
conducted in Los Angeles County (LAC) and in the San
Francisco Bay area (SFBA) and used similar protocols and
a common structured questionnaire administered in per-
son. The characteristics of the study population and partici-
pation rates have been previously described [15, 16].
Brieﬂy, newly diagnosed PCa cases were identiﬁed through
the LAC and Greater Bay Area cancer registries. At both
study sites, patients with intracapsular PCa were classiﬁed
as localized cases and patients with extracapsular extension
of the tumor, and/or extension into adjacent surrounding
tissue, or regional lymph nodes, or metastasis to other areas
of the body, were classiﬁed as advanced cases (Surveillance,
Epidemiology, and End Result [SEER] 1995 clinical and
pathologic extent of disease codes 41–85).
Study population
San Francisco Bay Area
Eligible localized cases aged 40–79 years diagnosed from
1997 to 1998 were randomly sampled among non-His-
panic White men (15% sample) and AA men (60% sam-
ple). Eligible advanced cases aged 40–79 years included all
non-Hispanic White men and all AA men diagnosed from
1997 to 2000. Controls were identiﬁed through random-
digit dialing and, for men aged ≥65 years, through ran-
dom selections from the rosters of beneﬁciaries of the
Health Care Financing Administration, and they were fre-
quency matched to advanced cases on race/ethnicity and
the expected 5-year age distribution of cases. The in-person
interview was completed by 208 localized cases (73 AA
and 135 non-Hispanic Whites), 568 advanced cases (118
AA and 450 non-Hispanic Whites), and 545 controls (90
AA and 455 non-Hispanic Whites).
Los Angeles County
AA, Hispanic, and non-Hispanic White males diagnosed
with PCa from 1999 to 2003 were identiﬁed by rapid case
ascertainment through the LAC Cancer Surveillance Pro-
gram. Controls were identiﬁed through a standard neigh-
borhood walk algorithm [17] and were matched to cases on
age (5 years) and race/ethnicity. The in-person interview
was completed by 1184 cases (351 AA, 333 Hispanics and
500 non-Hispanic Whites), including 631 with advanced
PCa and 553 with localized PCa, and 594 controls (163 AA,
122 Hispanics and 309 non-Hispanic Whites).
Blood or mouthwash samples were collected for 1164
advanced cases, 553 localized cases (in LAC only), and
1119 controls. Written informed consent was obtained
from all the study participants at the time of in-person
interview. The study received approval from the institu-
tional review boards at the Cancer Prevention Institute of
California and the University of Southern California.
Data collection
A structured questionnaire, administered at the partici-
pant’s home, asked about demographic background,
medical history, body size, tobacco use, and other life-
style factors. The interviewers also measured height and
weight. Usual dietary intake during the reference year
(calendar year before diagnosis for cases or before selec-
tion into the study for controls) was assessed using a
74-item food frequency questionnaire (FFQ) that was
adapted from the Block Health History and Habits
Questionnaire [18]. An aggregate level socioeconomic
status (SES) variable was derived from 2000 census data
as previously described [19]. Body mass index (BMI)
was calculated as self-reported weight (in kg) in the
reference year and divided by height (in meters)
squared measured at the time of the interview and cate-
gorized as normal weight (BMI < 25), overweight (BMI
25–29.9) and obese (BMI ≥ 30). Underweight men
(BMI < 18.5, n = 15) were grouped with normal-weight
men. For individuals with missing information on self-
reported weight (1 case and 1 control), BMI was
calculated using measured weight. For individuals who
declined height measurement (4.9% of cases, 4.8%
of controls), BMI was calculated using self-reported
height.
Tobacco consumption variables
The questionnaire assessed lifetime histories of smoking
(cigarettes, cigars, pipe), tobacco chewing, and use of
tobacco snuff. Information was collected on the ages at
which men started and stopped tobacco consumption,
and years and amount of tobacco consumption (ciga-
rettes per day, cigars per week, pipes per week, chewing
tobacco per week, cans of snuff per week). Ever tobacco
smoking (not including tobacco chewing or snuff) was
deﬁned as smoking at least one cigarette a day and/or
one cigar/pipe a week for 6 months or longer, and for-
mer smokers were deﬁned as individuals who quit smok-
ing prior to the reference year. The following variables
were evaluated: history of tobacco smoking (ever/never),
smoking status (never, former, current), age started to
smoke (years), duration of smoking (years), type of
tobacco used (cigarettes, cigars, pipes) and cigarettes
smoked per day (lifetime average), and pack-years of cig-
arette smoking (ratio of the number of cigarettes smoked
per day to 20 cigarettes, which is the current number of
1646 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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years smoked), and years passed since quitting smoking
among former smokers. Variables were dichotomized
based on the median value among controls who ever
smoked tobacco.
Polymorphisms data
As previously reported [20], genotype information was
available for 11 single-nucleotide polymorphisms (SNPs)
in eight genes reported to impact enzyme function:
GSTP1 Ile105Val (rs1695) [21], PTGS2 -765 G/C
(rs20417) [22], CYP1A2 -154 A/C (rs762551) [23],
CYP2E1 -1054C>T (rs2031920), EPHX1 Tyr113His
(rs1051740) [24], CYP1B1 Leu432Val (rs1056836) [25],
UGT1A6 Thr181Ala (rs1105879) [26], and NAT2
Ile114Thr, Arg197Gln, Gly286Glu and Arg64Gln
(rs1799930, rs1799931, rs1801279, rs180120) [27], in
addition to two genes that had copy number variants,
GSTM1 and GSTT1 [21]. NAT2 haplotypes were con-
structed using haplo.stats package in R (http://www.
R-project.org/). NAT2 haplotypes have been characterized
for their impact on protein function [28, 29]; consistent
with the existing classiﬁcation [30], we classiﬁed carriers
of two copies of the fast haplotype as “fast” and carriers
of all other haplotypes as “slow” phenotype. All genotypes
were obtained using Taqman assays, available “on
demand” from ABI (Applied Biosystems, Foster City,
CA), following manufacturer’s instructions. Call rates
were >97%. No differences were found between observed
genotypic frequencies and those expected assuming
Hardy–Weinberg Equilibrium.
Statistical analyses
The analyses of questionnaire data were based on 761
localized cases, 1199 advanced cases, and 1139 controls.
Analyses of genotype data were based on men with DNA
from blood, including 535 localized cases, 988 advanced
cases, and 800 controls. These individuals did not differ
from those without DNA with regard to age, calorie
intake, family history, SES and BMI at either study site
(data not shown).
To best correct for differences in race/ethnicity, SES
and the case/control ratio across the two study sites, we
created a variable that classiﬁed men according to study
site (SFBA or LAC), SES (5-level variable, as previously
described [19]) and race/ethnicity (non-Hispanic White,
AA, Hispanic), and used it to group individuals in condi-
tional logistic regression models that were used to esti-
mate odds ratios (OR) and 95% conﬁdence intervals
(CI). SES was collapsed into three categories (quintiles 1–
2, 3, 4–5) for SFBA subjects and four categories (quintiles
1, 2, 3, 4–5) for LAC subjects, leaving six SES/race groups
from SFBA and 12 from LAC. When evaluating smoking
tobacco, models were adjusted for age at diagnosis for
cases or selection into the study for controls (in years,
modeled as continuous), family history of PCa in ﬁrst-
degree relatives (no, yes), BMI (<25.0, 25.0–29.9,
≥30.0 kg/m
2), average lifetime consumption of alcohol
(grams/day), use of nonsmoking tobacco (snufﬁng or
chewing) (no, yes), cigar or pipe smoking (no, yes) if
evaluating only cigarette smoking (cigarettes/day or pack-
years), intake of red meat cooked at high temperature
(broiled, pan-fried or grilled, in g/day), which we previ-
ously reported to be associated with increased PCa risk,
and contributes to carcinogenic exposure [20, 31]. We
also considered possible confounding by total vegetable
consumption (g/day), total fruit consumption (g/day),
and total calorie intake (kcal/day) during the reference
year; however, inclusion of these covariates did not
change OR estimates by >10%, so they were not included
in ﬁnal models. All analyses were stratiﬁed by stage (local-
ized and advanced) and by race/ethnicity. Heterogeneity
by race within each stage was evaluated using a likelihood
ratio test comparing conditional logistic models that were
ﬁt with and without interaction terms of smoking vari-
ables and race.
Gene 3 smoking interaction analyses
We examined the potential modifying role of the selected
polymorphisms on the associations between tobacco
smoking and PCa risk using both two degree of freedom
(2-df) interaction tests by treating the three-level tobacco
smoking variables as categorical, and 1-df interaction tests
by treating these variables as ordinal. We have previously
reported the associations between these metabolic enzyme
polymorphisms and PCa risk [20]. For the gene x envi-
ronment analyses in this study, we evaluated one SNP for
seven metabolism genes and two copy number variants
(GSTP1, PTGS2, CYP1A2, CYP2E1, EPHX1, CYP1B1,
UGT1A6, GSTM1, and GSTT1), as well as the predicted
phenotype of the NAT2 enzyme determined by four SNPs
in the gene used to deﬁne high and low enzymatic activ-
ity, as possible modiﬁers of the associations with the fol-
lowing smoking variables: smoking status (never, former,
current), history of smoking tobacco (never, ever), age
start of smoking tobacco (never smoker, ≤18 years,
>18 years), smoking duration (never smoker, ≤29 years,
>29 years), cigarettes smoked per day (never cigarette
smoker, ≤20 cigarettes, >20 cigarettes), cigarette pack-
years (never cigarette smoker, ≤22 cigarette pack-years,
>22 cigarette pack-years), and years since quitting smok-
ing (never smoker, >21 years, ≤21 years). Gene 9 smok-
ing interaction models were adjusted for the same
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smoking on PCa risk.
All hypothesis tests were two sided and all analyses
were done using the statistical software Stata S/E 11.2
(STATA Corporation, College Station, TX).
Results
Socio-demographic and lifestyle characteristics, including
tobacco smoking, of cases and controls are presented in
Table 1. When compared to controls, localized and
advanced cases were more likely to report a family history
of PCa. Localized cases were of lower SES than controls.
Among controls, 67% had ever smoked tobacco and 18%
were current smokers during the reference year. They
consumed, on average, about a pack of cigarettes a day
and smoked for an average of 28.2 years. Tobacco smok-
ing characteristics by PCa stage and race/ethnicity are pre-
sented in Table S1. No substantial differences in smoking
characteristics were seen among races/ethnicities. Among
controls, 65% of non-Hispanic Whites were ever tobacco
smokers and smoked 30.7 pack-years compared to 73%
of AA who smoked 27.4 pack-years and 70% of Hispanics
who smoked 24.6 pack-years.
Characteristics of PCa cases by smoking status (never
smoker, quit >21 years ago, quit ≤21 years ago, current
smoker) are presented in Table S2. When compared to
never and former smokers, current smokers had a lower
BMI (P = 0.002), lower SES (P = 0.001), were more likely
to be non-Hispanic White or AA (P < 0.001), were of
younger age at PCa diagnosis (P < 0.001), had higher lev-
els of alcohol consumption during their lifetime
(P < 0.001), consumed more meat cooked at high tem-
perature (P < 0.001), had lower total vegetable consump-
tion (P < 0.001), and lower total fruit intake (P < 0.001).
When compared to former smokers, current smokers
were more likely to smoke a pack or less (P < 0.001) and
more likely to smoke for >29 years (P < 0.001).
Tobacco smoking and prostate cancer risk
We observed differences in the associations between
tobacco smoking variables and risk of localized PCa by
race/ethnicity (Table 2). Among AA, there was no evidence
of associations between localized PCa and any of the smok-
ing variables. Among Hispanic and non-Hispanic Whites,
ORs were generally elevated but were statistically signiﬁcant
only among non-Hispanic Whites. Among non-Hispanic
Whites, risk of localized PCa was increased by 50% for ever
smokers (OR = 1.5, 95% CI = 1.1–2.1), former smokers
(OR = 1.5, 95% CI = 1.1–2.1), and current smokers
(OR = 1.5; 95% CI = 0.9–2.4) compared to never smokers,
although the last comparison was not statistically signiﬁ-
Table 1. Socio-demographic and lifestyle characteristics of controls
and cases.
Controls
(N = 1139)
Localized PCa
cases
(N = 761)
Advanced
PCa cases
(N = 1199)
n (%) n (%) n (%)
Characteristics
Age at diagnosis (years)
<50 59 (5) 21 (3) 48 (4)
50–59 322 (29) 122 (16) 333 (28)
60–69 450 (40) 283 (38) 499 (42)
70+ 293 (26) 323 (43) 310 (26)
N 1135 754 1195
Mean (SD) 63.7 (9.1) 67.5 (8.8) 63.9 (8.5)
Family history of PCa
No 993 (88) 597 (79) 964 (81)
Yes 139 (12) 155 (21) 228 (19)
Body Mass Index (kg/m
2)
<25 290 (26) 199 (27) 294 (25)
25–29 514 (46) 374 (50) 579 (49)
≥30 320 (28) 176 (23) 317 (26)
Socio-economic status
1 (Low) 124 (11) 161 (21) 161 (13)
2 142 (13) 136 (18) 150 (13)
3 206 (18) 127 (17) 217 (18)
4 278 (24) 138 (18) 235 (20)
5 (High) 385 (34) 192 (26) 432 (36)
Race/ethnicity
Non-Hispanic
White
764 (67) 343 (45) 741 (62)
African-American 249 (22) 277 (37) 255 (21)
Hispanic 122 (11) 134 (18) 199 (17)
Center
SFBA 594 (52) 553 (73) 631 (53)
LAC 545 (48) 208 (27) 568 (47)
Ever smoked any tobacco
Yes 763 (67) 560 (74) 839 (70)
Smoked cigarettes for at least 6 months
Yes 707 (62) 531 (70) 782 (65)
Smoked cigars for at least 6 months
Yes 148 (13) 109 (14) 159 (13)
Smoked pipes for at least 6 months
Yes 198 (17) 127 (17) 220 (18)
Ever chewed tobacco
Yes 21 (2) 18 (2) 28 (2)
Ever snuffed tobacco
Yes 6 (1) 5 (1) 11 (1)
Tobacco smoking status (cigarettes/cigars/pipes)
Never 369 (33) 197 (26) 357 (30)
Former 550 (49) 409 (55) 608 (51)
Current 209 (18) 143 (19) 228 (19)
Age start of smoking tobacco (years)
N 759 552 835
Mean (SD) 18.5 (5.7) 18.4 (5.5) 18.3 (5.8)
Duration of smoking tobacco (years)
N 759 552 835
Mean (SD) 28.2 (14.8) 32.0 (15.8) 28.9 (15.6)
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smokers. OR estimates did not increase with increasing
duration or intensity of smoking. Among former smokers,
estimates were similar for men who quit >21 years
(OR = 1.5; 95% CI = 1.0–2.1) vs. ≤21 years (OR = 1.6;
95% CI = 1.1–2.3) prior to the reference year.
Table 3 presents associations between smoking variables
and risk of advanced PCa stratiﬁed by race/ethnicity.
Among non-Hispanic Whites, current smoking was asso-
ciated with an increased risk of advanced PCa when com-
pared to never smokers (OR = 1.4, 95% CI = 1.0–1.9).
No associations were observed among AA (OR = 0.8,
95% CI = 0.5–1.3) or Hispanics (OR = 0.5, 95%
CI = 0.2–1.0; p of heterogeneity test = 0.004). OR esti-
mates did not increase with increasing duration or inten-
sity of smoking. Among Hispanics, compared to never
smokers, we observed some borderline signiﬁcant associa-
tions for smokers with longer time since quitting and an
inverse association with current smoking, although the
number of current smokers was relatively small.
When restricting our analyses to ever smokers, we
examined whether the age at ﬁrst tobacco use modiﬁed
the associations between tobacco smoking duration, ciga-
rette pack-years, and smoking status (quit >21 years ago,
quit ≤21 years ago, current smoking) and PCa risk. There
was no evidence of effect modiﬁcation for either localized
or advanced disease among the variables considered (data
not shown).
Tobacco smoking, polymorphisms in
metabolism enzymes, and PCa risk
Interactions between each of the nine polymorphisms
and NAT2 predicted phenotype and tobacco smoking
variables were evaluated. We only observed evidence of
effect modiﬁcation for CYP1A2 -154A>C (rs762551) on
smoking status (never, former, current) (Table 4).
Among carriers of the CC genotype, current smoking was
associated with increased risk of PCa overall (OR = 2.2;
95% CI = 1.2–4.3, P-interaction = 0.008), localized PCa
(OR = 2.8; 95% CI = 1.2–6.9, P-interaction = 0.012),
and advanced PCa (OR = 1.9; 95% CI = 1.0–3.8, P-inter-
action = 0.043). These associations were not present
among carriers of the AA genotype. Analyses considering
other smoking variables (smoking duration, cigarette
pack-years, and age at ﬁrst tobacco use) showed similar
ﬁndings as those for smoking status; however, none
reached statistical signiﬁcance. Similar interaction ORs
were observed when stratifying by race/ethnicity and
including both localized and advanced PCa for non-
Hispanic Whites and AA (data not shown). This pattern
was not observed among Hispanics, although the number
of Hispanics was small (data not shown). No evidence
of interaction was observed for any of the other
polymorphisms or NAT2 predicted phenotype. We also
conducted exploratory analyses to consider all polymor-
phisms and NAT2 predicted phenotype jointly using
principal components analyses. We found no evidence
that components deﬁned by multiple polymorphism
modiﬁed the association between smoking and PCa risk
(data not shown).
Discussion
In this study, ever smoking was found to be associated
with localized PCa risk, particularly among non-Hispanic
Whites. Quitting smoking was also associated with local-
ized PCa. In contrast, being a current smoker was associ-
ated with risk of advanced PCa among non-Hispanic
White men. For both localized and advanced PCa, the
association with smoking was modiﬁed by a polymor-
phism in the carcinogen metabolism CYP1A2 gene. Over-
all, our ﬁndings lend support to a role for tobacco
smoking in PCa risk after taking into account both PCa
stage and race/ethnicity in the analyses.
In congruence with our ﬁndings, a population-based
case–control study in the U.S. reported that current
Table 1. Continued.
Controls
(N = 1139)
Localized PCa
cases
(N = 761)
Advanced
PCa cases
(N = 1199)
n (%) n (%) n (%)
Years passed since smoking cessation (former smokers only)
N 549 407 603
Mean (SD) 21.2 (12.3) 22.1 (13.9) 22.8 (12.9)
Cigarettes smoked (per day)
N 706 531 782
Mean (SD) 20.9 (14.5) 20.2 (14.9) 20.4 (14.8)
Cigarettes smoked (pack-years)
N 701 525 778
Mean (SD) 29.1 (26.4) 32.3 (31.0) 29.2 (28.1)
Alcohol intake (g/day)
N 1121 749 1188
Mean (SD) 12.0 (20.1) 12.9 (24.6) 12.4 (24.1)
Consumption of meat cooked at high temperature (g/day)
N 1131 758 1194
Mean (SD) 119 (86) 140 (111) 129 (95)
Vegetable intake (g/day)
N 1123 749 1189
Mean (SD) 137 (179) 145 (187) 134 (169)
Fruit intake (g/day)
N 1123 749 1189
Mean (SD) 114 (184) 116 (173) 104 (165)
Daily caloric intake
N 1096 717 1140
Mean (SD) 2627 (1079) 2845 (1137) 2853 (1137)
SFBA, San Francisco Bay Area; LAC, Los Angeles County.
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PCa when compared to non-smoking [32]. In that study,
PCa risk increased with increasing pack-years of cigarette
smoking, something we did not observe in our study.
Moreover, in contrast with our study, a stronger associa-
tion was observed between pack-years and aggressive PCa,
and quitting smoking was associated with reduced PCa
risk. However, our observations of former smokers having
an increased risk of localized PCa, and non-Hispanic
White current smokers having an increased risk of
advanced PCa, are consistent with ﬁndings from a 2010
meta-analysis of 24 prospective cohort studies showing
that both former and current smokers had an increased
risk of incident PCa, although stage and race/ethnicity
were not accounted for in the meta-analysis [1]. A large
cohort study including data from 10 European countries
(EPIC), which considered stage and grade, reported an
inverse association between localized and low-grade pros-
tate cancer (PCa) among smokers, which is in contrast
with our results that showed a positive association [33].
Table 2. Smoking characteristics and risk of localized prostate cancer by race/ethnicity.
All races/ethnicities Non-Hispanic Whites African-Americans Hispanics
Co/Ca OR
1 95% CI Co/Ca OR
1 95% CI Co/Ca OR
1 95% CI Co/Ca OR
1 95% CI
Heterog
p
2
Smoking Status (any smoking tobacco)
Never smoker 365/196 1.0
REF 265/93 1.0
REF 65/72 1.0
REF 35/31 1.0
REF
Former smoker 549/409 1.3 1.0–1.6 385/200 1.5 1.1–2.1 111/132 0.8 0.5–1.3 53/77 1.6 0.9–3.2 0.073
Current smoker 206/142 1.1 0.8–1.5 108/47 1.5 0.9–2.4 68/72 0.7 0.4–1.2 30/23 1.1 0.5–2.3
Use of smoking tobacco
No 365/196 1.0
REF 265/93 1.0
REF 65/72 1.0
REF 35/31 1.0
REF
Yes 756/553 1.3 1.0–1.6 494/248 1.5 1.1–2.1 179/204 0.8 0.5–1.2 83/101 1.4 0.8–2.8 0.057
Age at ﬁrst tobacco use (years)
Never smoker 365/196 1.0
REF 265/93 1.0
REF 65/72 1.0
REF 35/31 1.0
REF
>18 292/217 1.3 1.0–1.7 187/100 1.5 1.0–2.0 78/82 0.7 0.4–1.2 27/35 1.4 0.6–3.2
≤18 463/334 1.2 1.0–1.6 306/147 1.6 1.1–2.4 101/122 0.9 0.5–1.4 56/65 1.4 0.7–2.9 0.132
p-trend 0.106 0.040 0.640 0.354
Smoking duration (years)
Never smoker 365/196 1.0
REF 265/93 1.0
REF 65/72 1.0
REF 35/31 1.0
REF
≤29 386/243 1.2 1.0–1.6 272/129 1.5 1.1–2.2 78/77 0.7 0.5–1.3 36/37 1.4 0.6–2.9 0.293
>29 369/308 1.3 1.0–1.6 221/118 1.5 1.1–2.8 101/127 0.8 0.5–1.3 47/63 1.5 0.7–3.0
p-trend 0.081 0.022 0.476 0.293
Cigarettes smoked per day
421/224 1.0
REF 312/113 1.0
REF 74/80 1.0
REF 35/31 1.0
REF 0.088
≤20 503/404 1.2 0.9–1.6 292/152 1.5 1.1–2.0 140/169 0.9 0.6–1.3 71/83 1.3 0.7–2.5
>20 196/121 1.2 0.9–1.6 154/76 1.5 1.0–2.3 30/27 0.6 0.3–1.1 12/18 2.1 0.7–5.9
p-trend 0.187 0.017 0.123 0.174
Cigarette Pack-years
Never cig.
smoker
421/224 1.0
REF 312/113 1.0
REF 74/80 1.0
REF 35/31 1.0
REF 0.161
≤22 357/250 1.2 0.9–1.5 210/105 1.5 1.1–2.2 98/91 0.7 0.5–1.2 49/54 1.4 0.7–2.8
>22 342/275 1.3 1.0–1.7 236/123 1.5 1.1–2.1 72/105 1.0 0.6–1.6 34/47 1.6 0.7–3.3
p-trend 0.039 0.019 0.998 0.253
Years since quitting smoking tobacco
Never smoker 365/196 1.0
REF 265/93 1.0
REF 65 1.0
REF 35/31 1.0
REF 0.314
Quit >21 years
ago
274/192 1.3 1.0–1.7 202/108 1.5 1.0–2.1 52 0.8 0.5–1.4 20/30 1.3 0.5–3.2
Quit ≤21 years
ago
274/215 1.3 1.0–1.7 183/91 1.6 1.1–2.3 58 0.9 0.5–1.5 33/46 1.8 0.8–3.8
Current smoker 206/142 1.1 0.8–1.5 108/47 1.5 1.0–2.4 68 0.7 0.4–1.2 30/23 1.1 0.5–2.5
p-trend 0.242 0.023 0.249 0.568
1Adjusted for age at diagnosis (years), family history of PCa, body mass index, alcohol consumption (g/day), total intake of meat cooked at high
temperature (g/day), any lifetime use of nonsmoking tobacco snuff/chew, use of cigar/pipe for at least 6 months if evaluating cigarette smoking
(per day and pack-years).
2Test of heterogeneity of ORs by race/ethnicity.
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A. Shahabi et al. Smoking, Metabolic Enzymes Polymorphisms, and Risk of Prostate CancerThis study also reported no signiﬁcant association with
smoking among advanced and high-grade cases. In con-
trast, the Japan Public Health Center-based prospective
study (JPHC study), which included over 48,000 men,
and a study using the Shared Equal Access Regional Can-
cer Hospital (SEARCH) cohort both found a positive
association between smoking and diagnosis of advanced
PCa [34, 35]. Based on the available literature the 2014
Surgeon General’s Report on smoking and tobacco use
concluded that there is suggestive evidence showing
smoking to be a risk factor of being diagnosed with
advanced stage or high-grade PCa, which is a risk factor
for progression and death [36]. Similar to 2010 meta-
analyses mentioned above, this report highlighted the
scarcity of studies that took into account stage and grade
at diagnosis.
As with other tobacco-related cancers, a possible mech-
anism by which tobacco smoking might inﬂuence PCa
risk is the action of tobacco-related carcinogens that
could induce DNA damage in the prostate. These muta-
genic carcinogens can be endogenously metabolized to
their active forms, which upon reaching the target tissues
can bind to DNA. Alternatively, they can be detoxiﬁed to
less active forms that can be readily excreted from the
body. Carcinogen metabolism enzymes are responsible for
the detoxiﬁcation or activation of mutagenic carcinogens
and are coded by genes known to be variable in the pop-
ulation [37]. In this study, we found that the association
between smoking status and PCa risk was modiﬁed by
CYP1A2 -154A>C (rs762551), a gene that codes for an
enzyme that plays a key role in the metabolism of many
drugs, such as caffeine, and in the activation of various
tobacco carcinogens, including HCAs and PAHs [38–42].
We observed that the association between current smok-
ing status and PCa risk seemed restricted to carriers of
one or two copies of the C allele. CYP1A2 is an induc-
ible phase I metabolizing enzyme highly active in the
liver, where it plays a predominant role in the activation
of HCAs [40], such as those found in tobacco, to reac-
tive species that can undergo further activation in the
liver or detoxiﬁcation. CYP1A2 mRNA is also expressed
in prostate tissue [43–45]. CYP1A2 expression is variable
in the general population and the CYP1A2 -154A>C
polymorphism may partially explain the observed vari-
ability in CYP1A2 inducibility, with the protein coded by
the A allele being correlated with higher enzymatic activ-
ity than the one coded by the C allele [42]. We have
previously reported that the association between well-
done cooked red meat, known to accumulate HCAs, and
colorectal cancer was stronger among carriers of the C
allele [46]. A meta-analysis of 19 case–control studies
further showed that the CC genotype is associated with
an increased risk of various types of cancer combined
(including breast, colorectal, lung, pancreatic, ovarian,
stomach, and bladder) and a signiﬁcant increase in risk
among Caucasians [47]. Furthermore, other studies
showed that low activity of CYP1A2 was associated with
risk of testicular cancer [48] and PCa [49]. A possible
Table 4. Smoking status, CYP1A2 (rs7662551) genotype, and risk of prostate cancer by cancer stage.
CYP1A2 A/A A/C C/C P-interaction
All cases
Smoking status Co Ca OR
1 95% CI Co Ca OR
1 95% CI Co Ca OR
1 95% CI
Never 126 224 1.0
REF 102 159 1.0
REF 23 40 1.0
REF 0.008
Former 170 382 1.2 0.9–1.6 164 319 1.0 0.8–1.3 42 63 1.0 0.6–1.5
Current 88 136 0.9 0.6–1.2 52 121 1.4 1.0–2.0 10 36 2.2 1.2–4.3
p-trend 0.601 0.066 0.031
Localized cases
Smoking status Co Ca OR
1 95% CI Co Ca OR
1 95% CI Co Ca OR
1 95% CI
Never 126 70 1.0
REF 102 55 1.0
REF 23 13 1.0
REF 0.016
Former 170 131 1.4 1.0–2.2 164 120 1.2 0.9–1.7 42 25 1.0 0.5–2.2
Current 88 39 0.8 0.5–1.4 52 49 1.5 0.9–2.4 10 16 2.8 1.1–6.9
p-trend 0.710 0.075 0.038
Advanced cases
Smoking status Co Ca OR
1 95% CI Co Ca OR
1 95% CI Co Ca OR
1 95% CI
Never 126 154 1.0
REF 102 104 1.0
REF 23 27 1.0
REF 0.043
Former 170 251 1.1 0.8–1.5 164 199 1.0 0.7–1.3 42 38 0.9 0.5–1.5
Current 88 97 0.9 0.8–1.5 52 72 1.3 0.9–1.9 10 20 1.9 1.0–3.8
p-trend 0.620 0.238 0.148
1Odds ratios derived from a common baseline model that includes the genotype, smoking status, and interaction terms between genotype and
smoking status. ORs are adjusted for age at diagnosis (years), family history of PCa, body mass index, alcohol consumption (g/day), total intake of
meat cooked at high temperature (g/day), any lifetime use of nonsmoking tobacco snuff/chew.
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Smoking, Metabolic Enzymes Polymorphisms, and Risk of Prostate Cancer A. Shahabi et al.explanation for these ﬁndings is that slower activation of
HCAs in the liver by CYP1A2 may allow HCAs to
remain in the body’s circulation longer, which could
result in greater amounts of HCAs reaching other organs
and tissues, such as the prostate. We cannot exclude,
however, the possibility that our ﬁnding might be a false
positive; Bonferroni adjustment of the CYP1A2 -154A>C
by smoking interaction P-value by the number of SNPs/
phenotypes tested (n = 10) would render an interaction
P-value of borderline signiﬁcance (P = 0.08). Since
CYP1A2 is heavily involved in caffeine metabolism, we
also considered frequency of coffee intake in the interac-
tion models to take into account possible confounding,
but ORs did not change by >10%.
Screening bias has been identiﬁed as a possible limita-
tion in previous studies, and could be present if tobacco
smoking patterns were correlated with PCa screening,
speciﬁcally prostate-speciﬁc antigen (PSA) screening [3].
We evaluated potential confounding by PSA screening
during the 5 years prior to the reference year among the
cases and controls from the SFBA study site, for whom
we had data on PSA screening. Including PSA screening
in the model with other covariates did not change the
OR estimates for any of the smoking variables by >10%
and was therefore not included in the ﬁnal model. Fur-
thermore, there was no statistical difference in PSA
screening when comparing cases with controls: 76% of
controls, 80% of localized cases, and 71% of advanced
cases reported previous PSA screening.
The overall strengths of this study include the utiliza-
tion of a population-based study design with cases
obtained from two SEER cancer registries, a large sample
size of cases and controls, a multiethnic population that
includes non-Hispanic White, AA, and Hispanic men,
oversampling of advanced cases, and detailed information
on lifestyle and other characteristics. Another strength is
the consideration of genetic variation in tobacco carcino-
gen metabolism enzymes to examine gene by environment
interactions. Among the limitations of this study is the
inclusion of only a few selected functional SNPs for each
candidate gene, which did not allow us to comprehen-
sively consider all their genetic variation. Other limita-
tions include the lack of data on environmental tobacco
exposure, which may have introduced some exposure
misclassiﬁcation and ﬁnally, small sample sizes when
stratifying the analyses by multiple factors (stage, race/
ethnicity, age at diagnosis), which reduced our statistical
power to detect possible associations.
In summary, our ﬁndings support a role for tobacco
smoking and risk of PCa, and suggest that ever smokers,
including those who quit, are at increased risk of having
localized PCa, whereas current smokers have a statistically
signiﬁcant increased risk of advanced PCa. Moreover, our
gene-environment analyses support a role for tobacco car-
cinogens in PCa risk, further strengthening an association
between tobacco smoke and PCa risk.
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